Search

Your search keyword '"Kambiz Rahbar"' showing total 192 results

Search Constraints

Start Over You searched for: Author "Kambiz Rahbar" Remove constraint Author: "Kambiz Rahbar"
192 results on '"Kambiz Rahbar"'

Search Results

1. Early treatment response assessment with [177Lu]PSMA whole-body-scintigraphy compared to interim PSMA-PET

2. Multivariable models of outcomes with [177Lu]Lu-PSMA-617: analysis of the phase 3 VISION trialResearch in context

3. Digital Image Enhancement Through Bi-Histogram Equalization Using Entropy-Based Plateau Limit

4. Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients

5. The prognostic potential of alkaline phosphatase and lactic acid dehydrogenase in bmCRPC patients without significant PSA response under enzalutamide

6. Bone Age Assessment Using Content-Based Image Retrieval System Using VGG-19 Deep Neural Network

7. Outcome Prediction in Patients With Large B-cell Lymphoma Undergoing Chimeric Antigen Receptor T-cell Therapy

8. Real-world effectiveness, long-term safety and treatment pathway integration of radium-223 therapy in patients with metastatic castration-resistant prostate cancer

9. Optimizing PSMA Radioligand Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Meta-Analysis

10. PSMA Theranostics: Current Status and Future Directions

11. Prostate specific membrane antigen (PSMA) expression in non-small cell lung cancer.

12. The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone

21. Safety and Survival Outcomes of177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior223Ra treatment: The RALU Study

22. Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

24. Interdisziplinärer Expertenkonsensus zu Innovationen der bildgebenden Diagnostik und radionuklidbasierten Therapien des fortgeschrittenen Prostatakarzinoms

26. [18F]-PSMA-1007-PET for evaluation of kidney function

29. The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [177Lu]Lu-PSMA-617: a WARMTH multicentre study

31. Safety and Survival Outcomes of Lutetium-177-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with prior Radium-223 treatment: The RALU Study

32. Diagnostic efficiency of hybrid imaging using PSMA ligands, PET/CT, PET/MRI and MRI in identifying malignant prostate lesions

33. PSMA-Radioligandentherapie könnte Nuklearmedizin vor infrastrukturelle Herausforderungen stellen: Ergebnisse einer Basiskalkulation zur Kapazitätsplanung nuklearmedizinischer Betten im deutschen Krankenhaussektor

34. Development and validation of a multigenomic liquid biopsy (PROSTest) for prostate cancer detection

35. Prediction of early prostate cancer recurrence using a liquid biopsy approach

36. Time interval between radium-223 (223Ra) therapy and Lutetium-177–prostate-specific membrane antigen (177Lu-PSMA) treatment and outcomes in the RALU study

37. Total tumor volume reduction and low PSMA expression in patients receiving Lu-PSMA therapy

38. Somatostatin Receptor–Targeted Radioligand Therapy in Head and Neck Paraganglioma

40. PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis

41. Diagnostic Accuracy of 18F-PSMA-1007 PET/CT Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence

42. Lokale Therapieverfahren neuroendokriner Tumoren mit dem Schwerpunkt nuklearmedizinische Optionen

43. Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving 177Lu-PSMA-617 Radioligand Therapy

44. Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)

45. PSMA radioligand therapy in patients with advanced prostate cancer

46. Incremental diagnostic value of [18F]tetrafluoroborate PET-CT compared to [131I]iodine scintigraphy in recurrent differentiated thyroid cancer

47. Radioligand therapy using [177Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysis

48. Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification : A post-hoc analysis of the PETAL trial

49. Safety and survival outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177–prostate-specific membrane antigen (177Lu-PSMA) after radium-223 (223Ra) : Interim analysis of the RALU study

50. Dosimetry of 177Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer : Results from the VISION trial sub-study

Catalog

Books, media, physical & digital resources